Rhumbline Advisers Acquires 4,497 Shares of Janux Therapeutics, Inc. $JANX

Rhumbline Advisers grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 11.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,650 shares of the company’s stock after buying an additional 4,497 shares during the quarter. Rhumbline Advisers owned 0.07% of Janux Therapeutics worth $1,152,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of JANX. Avanza Fonder AB boosted its holdings in Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company’s stock valued at $86,000 after acquiring an additional 444 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Janux Therapeutics by 3.0% during the first quarter. New York State Common Retirement Fund now owns 16,435 shares of the company’s stock valued at $444,000 after purchasing an additional 471 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Janux Therapeutics by 20.4% in the first quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock worth $109,000 after purchasing an additional 686 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Janux Therapeutics by 6.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company’s stock worth $320,000 after purchasing an additional 727 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Janux Therapeutics in the fourth quarter worth $59,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analysts Set New Price Targets

JANX has been the subject of several analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Raymond James Financial began coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an “outperform” rating and a $65.00 price objective for the company. Truist Financial assumed coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 target price on the stock. Piper Sandler initiated coverage on Janux Therapeutics in a report on Monday, August 18th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, Guggenheim initiated coverage on Janux Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of “Buy” and an average target price of $78.31.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $23.45 on Friday. The firm’s 50 day moving average price is $24.45 and its 200-day moving average price is $26.10. Janux Therapeutics, Inc. has a 52-week low of $21.97 and a 52-week high of $71.71. The company has a market cap of $1.41 billion, a PE ratio of -13.03 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). On average, analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.